New research presented at the European Respiratory Society (ERS) International Congress being held virtually until September 9, 2020, suggests “social smokers” are more than twice as likely to die of lung disease and over 8-times as likely to die of lung cancer vs non-smokers.
The study, titled “Association of low-intensity smoking with respiratory and lung cancer mortality,” also found that the risk of lung cancer mortality for “social smokers” (those who smoke <10 cigarettes/day) is not substantially lower vs heavy smokers (those who smoke ≥20 cigarettes/day).
The researchers – led by Pallavi Balte, PhD, and Elizabeth Oelsner, MD, MPH, both at Columbia University Medical Center in New York – noted that their study suggests that cutting down, or combining, fewer cigarettes with vaping, is not a substitute for quitting.
“Everyone knows that smoking is bad for you, but it’s easy to assume that if you only smoke a little, the risks won’t be too high,” said Balte to the virtual conference, according to an ERS press release. “Previous research suggests that people are cutting down on smoking, for example in the USA the proportion of smokers smoking less than ten cigarettes per day has increased from 16% to 27%. So, we wanted to study the risks to social smokers compared to people who don’t smoke and compared to heavier smokers.”
The study included 18 730 people selected from a multi-ethnic sample of the general US population; mean age was 61 years old, 56% women, 69% white, 13% current smokers. The median follow-up was 17 years, during which 649 participants died from respiratory causes and 560 died from lung cancer.
Smoking is dangerous, regardless of whether you are a heavy smoker or a social smoker, so if you don’t want to die of lung cancer or respiratory disease, the best action is to quit completely.
Researchers calculated the death rates from respiratory disease and lung cancer and then compared these rates between non-smokers, social smokers, and heavy smokers. Researchers took account of other factors that can influence death rates including age, sex, race, education attainment, and body weight.
The results showed that social smokers were 2.5 times as likely to die of respiratory disease and 8.6 times as likely to die of lung cancer vs non-smokers. Social smokers had around half the rate of death from respiratory diseases as heavy smokers, however, their rate of lung cancer death was two-thirds that of heavy smokers.
“You might think that if you only smoke a few cigarettes a day you are avoiding most of the risk. But our findings [sis] suggesting that social smoking is disproportionately harmful. Smoking is dangerous, regardless of whether you are a heavy smoker or a social smoker, so if you don’t want to die of lung cancer or respiratory disease, the best action is to quit completely,” added Balte.
“Social Smoking” Linked to Disproportionately High Risk of Death from Lung Disease, Lung Cancer
New research presented at the virtual European Respiratory Society International Congress showed "social smokers" are more than twice as likely to die of lung disease vs non-smokers.
New research presented at the European Respiratory Society (ERS) International Congress being held virtually until September 9, 2020, suggests “social smokers” are more than twice as likely to die of lung disease and over 8-times as likely to die of lung cancer vs non-smokers.
The study, titled “Association of low-intensity smoking with respiratory and lung cancer mortality,” also found that the risk of lung cancer mortality for “social smokers” (those who smoke <10 cigarettes/day) is not substantially lower vs heavy smokers (those who smoke ≥20 cigarettes/day).
The researchers – led by Pallavi Balte, PhD, and Elizabeth Oelsner, MD, MPH, both at Columbia University Medical Center in New York – noted that their study suggests that cutting down, or combining, fewer cigarettes with vaping, is not a substitute for quitting.
“Everyone knows that smoking is bad for you, but it’s easy to assume that if you only smoke a little, the risks won’t be too high,” said Balte to the virtual conference, according to an ERS press release. “Previous research suggests that people are cutting down on smoking, for example in the USA the proportion of smokers smoking less than ten cigarettes per day has increased from 16% to 27%. So, we wanted to study the risks to social smokers compared to people who don’t smoke and compared to heavier smokers.”
The study included 18 730 people selected from a multi-ethnic sample of the general US population; mean age was 61 years old, 56% women, 69% white, 13% current smokers. The median follow-up was 17 years, during which 649 participants died from respiratory causes and 560 died from lung cancer.
Researchers calculated the death rates from respiratory disease and lung cancer and then compared these rates between non-smokers, social smokers, and heavy smokers. Researchers took account of other factors that can influence death rates including age, sex, race, education attainment, and body weight.
The results showed that social smokers were 2.5 times as likely to die of respiratory disease and 8.6 times as likely to die of lung cancer vs non-smokers. Social smokers had around half the rate of death from respiratory diseases as heavy smokers, however, their rate of lung cancer death was two-thirds that of heavy smokers.
“You might think that if you only smoke a few cigarettes a day you are avoiding most of the risk. But our findings [sis] suggesting that social smoking is disproportionately harmful. Smoking is dangerous, regardless of whether you are a heavy smoker or a social smoker, so if you don’t want to die of lung cancer or respiratory disease, the best action is to quit completely,” added Balte.
FDA Approves TSLP Inhibitor Tezepelumab for Chronic Rhinosinusitis With Nasal Polyps
Tezepelumab's approval marks the first for a TSLP-targeting biologic for CRSwNP, backed by WAYPOINT trial data showing sustained symptom and polyp reduction.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Telemedicine Improves Inhaler Technique, QoL Following Severe Exacerbation of COPD
Telemedicine follow-up after hospital discharge for COPD exacerbation was significantly more effective than standard care and received high patient satisfaction scores.
NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half
In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.
GRAIL to Showcase New Data for Galleri Multicancer Early Detection Test at Key Fall Meetings
New data will be shared from the PATHFINDER 2 study in asymptomatic patients and the SYMPLIFY study in patients experiencing symptoms.
FDA Updates Albuterol/Budesonide Label to Include Evidence of Exacerbation Risk Reduction in Mild Asthma
The updated prescribing information includes phase 3b BATURA trial results showing a 46% reduction in severe exacerbations in mild asthma vs albuterol.
FDA Approves TSLP Inhibitor Tezepelumab for Chronic Rhinosinusitis With Nasal Polyps
Tezepelumab's approval marks the first for a TSLP-targeting biologic for CRSwNP, backed by WAYPOINT trial data showing sustained symptom and polyp reduction.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Telemedicine Improves Inhaler Technique, QoL Following Severe Exacerbation of COPD
Telemedicine follow-up after hospital discharge for COPD exacerbation was significantly more effective than standard care and received high patient satisfaction scores.
NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half
In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.
GRAIL to Showcase New Data for Galleri Multicancer Early Detection Test at Key Fall Meetings
New data will be shared from the PATHFINDER 2 study in asymptomatic patients and the SYMPLIFY study in patients experiencing symptoms.
FDA Updates Albuterol/Budesonide Label to Include Evidence of Exacerbation Risk Reduction in Mild Asthma
The updated prescribing information includes phase 3b BATURA trial results showing a 46% reduction in severe exacerbations in mild asthma vs albuterol.